How is Delic creating a legal psychedelic ecosystem

In 2019, a new kind of wellness business sprouted – a legal psychedelic drug company. We spoke with Matt Stang, the co-founder and CEO of Delic Corp to learn more about their mission as well as any strategies they utilized to build a publicly traded, legal psychedelic ecosystem. Matt Stang spent twenty years pioneering the […]

The post How is Delic creating a legal psychedelic ecosystem appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

What Does Hemp Legalization Mean for Selling CBD

As 2018 drew to
an end, the cannabis industry faced a seismic change: Congress had passed (and President
Trump had signed) the 2018 Farm Bill, thereby legalizing hemp — defined as
cannabis with less than 0.3 percent THC. Cannabis reporters’ inboxes filled up
with statements from industry folk “celebrating” and “applauding” the federal
government for removing industrial hemp from the list of federally controlled
substances. They were mostly celebrating one thing: the cannabinoid CBD now had
a path to mainstream legality.

Despite hemp’s murky legal status before the Farm Bill, CBD has become a huge health-and-wellness trend, popping up in coffee shops, cocktail bars and health-food stores all over the country. The hemp-CBD industry ballooned to $590 million in 2018, according to Bethany Gomez, director of research for the Brightfield Group. Hemp farmers can earn $200 to $400 an acre if their crops are going into textiles, building materials and plastics. But crops heading towards CBD extraction can fetch thousands of dollars per acre, reported the Wall Street Journal.

So what does hemp legalization mean for cannabinoids such as CBD being treated as a commodity?

Unfortunately for
some hemp operators, the Farm Bill wasn’t immediately the miracle legislation
that they’d hoped for. After the bill’s passage, as the Department of
Agriculture continues to craft the rules around hemp, business owners have seen
their CBD products confiscated by U.S. Food and Drug Administration officials
and their hemp shipments seized by law enforcement for crossing state lines. The
FDA has insisted that CBD is a
drug, and therefore illegal to add to other products without FDA approval. While
the industry continues to grow, it’s still unclear how the federal agency will
manage the disconnect between CBD as a federally regulated drug and a thriving
industry that views the non-intoxicating cannabinoid as a dietary supplement.

A lack of clarity hasn’t stopped traditional retailers from jumping into the space, with both DSW and Neiman Marcus announcing in January that they would start stocking CBD cosmetics. The CBD trend is only poised to grow as mainstream companies get in on the action. But it isn’t only CBD: hemp plants can produce other cannabinoids, too.

The Other Players in the Entourage

The CBD trend will “absolutely 100%” extend to other cannabinoids, said Cristina Buccola, an attorney who has worked with marijuana and hemp companies. “There’s already a commodification of other cannabinoids, including CBG and CBDV… As more people get educated and as research avenues open up — it’s just a matter of time.”

Indeed, cannabis businesses are already developing ways to produce minor cannabinoids in greater quantities, hoping to harness their (still little-researched) therapeutic properties. Companies like Ebbu, which was acquired by Canadian cannabis giant Canopy Growth last October, see a future in which the cannabis market will be dominated by isolated cannabinoids. Other companies are looking to produce cannabinoids without the help of cannabis, such as growing them on genetically edited yeast.

The proposition
is sure to cause consternation among cannabis consumers who tout the entourage
effect of the cannabis plant. But for a more cannabis-naïve consumer, the
promise of consistent formulations could be an attractive selling point. Then
there’s the pharmaceutical industry, which has long been isolating compounds
from plants to turn them into drugs.

Pharma companies have already developed an interest in other cannabinoids. In February 2018, the FDA gave orphan drug status to a cannabigerol (CBG) derivative produced by Emerald Health Pharmaceuticals for treating Huntington’s disease. Across the pond, the European Medicines Agency gave orphan drug status for cannabidivarin (CBDV) to GW Pharmaceuticals, the company that also produces the first FDA-approved CBD drug in the U.S.

THC’s Status in the Cannabinoid Market

Given that industrial hemp can produce all these minor cannabinoids, where does that leave the much-appreciated THC? After all, there’s no meaningful difference between marijuana and industrial hemp plants, as they are now legally defined, using the arbitrary designation that hemp contains less than 0.3 percent THC. Researchers and businesses alike will find it easier to work with industrial hemp, and may choose to focus their efforts there until the feds fully legalize cannabis. But there’s definitely a long way to go before cannabinoids are truly a commodity.

If the U.S.
repeals cannabis prohibition, there are other countries to contend with.
Recently, narcotics officers raided a beauty supply store in Singapore,
confiscating a bunch of mascara. The offense? The mascara contained oil derived
from hemp seeds. Has anyone told the Singaporean authorities that the stuff
won’t get you high?

“We’re still
overcoming the stigma of cannabis in so many ways, including educating people
about THC and industrial hemp, and eliminating concerns about ‘getting high,’”
said Buccola, who demurred when asked to prognosticate about the future of the
marijuana and hemp markets.

“I don’t think we
can even put our arms around what that looks like because there are so many
layers of prohibition and misinformation to peel back before we can understand
the potential of either market.”

TELL US, do you choose products based on their cannabinoid profiles?

Originally published in print edition of Cannabis Now. LEARN MORE

The post What Does Hemp Legalization Mean for Selling CBD appeared first on Cannabis Now.

New Clinical Trial Will Examine Effects of Cannabis Compound on Autism

A New York clinical trial will study the effects of the cannabis compound cannabidivarin, or CBDV, on patients with autism, according to a report from CNN. The study at the Montefiore Medical Center will examine the effects of CBDV on irritability and repetitive behaviors in children with autism spectrum disorder.

Dr. Eric Hollander, director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital and the lead researcher on the study, told CNN that previous research has shown that CBDV may have potential as a treatment for autism spectrum disorders.

“In some of the animal models that are similar to autism, it was found that CBDV had important effects on social functioning, on decreasing seizures, on increasing cognitive function, and in reducing compulsive or repetitive behavior,” Hollander said. “So for that reason, we wanted to apply that to autism.”

The CBDV formulation being used in the study is produced in the U.K. by GW Pharmaceuticals, the manufacturer of the only FDA-approved cannabis medicine Epidiolex. The drug has been approved for use in the U.S. and European Union to treat two serious disorders that cause childhood epilepsy. Dr. Geoffrey Guy, the founder of GW, said that epilepsy and autism share some common symptoms.

“When you look at these—loss of cognitive function, poor socializing skills, poor language skills—what you’re looking at is a phenotype very similar to autism,” Guy told Dr. Sanjay Gupta in an interview for the CNN special “Weed 5: The CBD Craze.” “In my mind, epilepsy and autism-type presentations are on the same continuum.”

Holand believes that autism and epilepsy may have similar underlying causes and says that CBDV has shown some success treating seizure disorders, giving him hope it may also be effective for autism patients.

“There’s some abnormal electrical activity even though they don’t have seizures, for example,” Hollander told Gupta. “And we had previously shown that when we give anticonvulsants that decrease the electrical activity, or the spikes, some of the disruptive behaviors, or the irritability, actually get better.”

“And that was one of our thoughts, why this CBDV could be helpful,” Hollander added. “Because if it helps with epilepsy and it helps in terms of decreasing the spike activity, we might also get improvement in the some of the aggression, or the self-injury, or the temper tantrums.”

Some Experts Wary About Cannabis

Dr. Alexander Kolevzon, the clinical director of the Seaver Autism Center at Mount Sinai who is not involved in the study, said that while he is encouraged by the potential of cannabis-based medications, it is still too early to tell if it’s an effective medication for patients with autism spectrum disorder.

“The field of autism has a long history of enthusiasm for many treatments based on small pilot studies and anecdotal accounts,” Kolevzon said. “However, often when these treatments are tested rigorously in larger studies, the benefits are not significantly different than that of placebo.”

Montefiore Medical Center is currently recruiting volunteers to participate in the study. Participants must be children 5 to 18 years old with autism spectrum disorder.

The post New Clinical Trial Will Examine Effects of Cannabis Compound on Autism appeared first on High Times.